Zhou S F
School of Health Sciences, RMIT University, Bundoora, Victoria, Australia.
Drug Discov Ther. 2008 Dec;2(6):305-32.
The multidrug resistance associated proteins (MRP1, MRP2, MRP3, MRP4, MRP5, MRP6, MRP7, MRP8 and MRP9) belongs to the ATP-binding cassette superfamily (ABCC family) of transporters expressed differentially in the liver, kidney, intestine and blood-brain barrier. MRPs transport a structurally diverse array of endo- and xenobiotics and their metabolites (in particular conjugates) and are subject to induction and inhibition by a variety of compounds. An increased efflux of natural product anticancer drugs and other anticancer agents by MRPs in cancer cells is associated with tumor resistance. These transporting proteins play a role in the absorption, distribution and elimination of various compounds in the body. There are increased reports on the clinical impact of genetic mutations of genes encoding MRP1-9. Therefore, MRPs have an important role in drug development, and a better understanding of their function and regulating mechanism can help minimize and avoid drug toxicity, unfavourable drug-drug interactions, and to overcome drug resistance.
多药耐药相关蛋白(MRP1、MRP2、MRP3、MRP4、MRP5、MRP6、MRP7、MRP8和MRP9)属于ATP结合盒超家族(ABCC家族)转运蛋白,在肝脏、肾脏、肠道和血脑屏障中差异表达。MRP转运结构多样的内源性和外源性物质及其代谢产物(特别是结合物),并受到多种化合物的诱导和抑制。癌细胞中MRP使天然产物抗癌药物和其他抗癌剂的外排增加与肿瘤耐药性相关。这些转运蛋白在体内各种化合物的吸收、分布和消除中发挥作用。关于编码MRP1 - 9的基因突变的临床影响的报道越来越多。因此,MRP在药物开发中具有重要作用,更好地了解其功能和调节机制有助于最小化和避免药物毒性、不良的药物相互作用,并克服耐药性。